Neutre
Johnson & Johnson's stock remains steady amid Kenvue stake sale and pharma growth.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
In the past 24 hours, Johnson & Johnson's stock has maintained stability, reflecting the company's ongoing transition following the 2023 Kenvue consumer-health separation. The latest quarterly results highlight mid-single-digit revenue growth and resilient margins, driven by expanding pharmaceutical and medtech operations.
Points clés
- Johnson & Johnson's stock holds steady as Kenvue stake sale and pharma growth reshape the group.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
